CVM Seeks Comments on Virginiamycin Prototype Risk Assessment

摘要

The Center for Veterinary Medicine (CVM) has completed its virginia-mycin risk assessment, which will serve as a prototype for looking at the indirect risks of resistance from the use of antimicrobials in food animals, and is seeking comments on the assessment. CVM conducted the assessment, which was released in late November, to determine whether pathways exist to link food-animal uses of virginiamycin, a member of the streptograrnin class of antimicrobials, with resistance to other streptogramins used in human medicine.